- Treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis.
- Treatment of iron deficiency anemia in patients with chronic kidney disease not on dialysis.
- Binds phosphorous and precipitates it as ferric phosphate.
- After being transported through enterocytes into the blood, oxidized ferric iron circulates bound to transferrin where it is incorporated into hemoglobin.
- Maintenance of normal phosphorous levels.
- Resolution of iron deficiency anemia.
Absorption: Some absorption follows oral administration and may lead to iron overload.
Metabolism and Excretion: Following binding, precipitated ferric phosphate is excreted in stool.
TIME/ACTION PROFILE (lowering of serum phosphorous)
|PO||within 1 wk||unknown||unknown|
- Iron overload syndromes including hemochromatosis.
Use Cautiously in:
- GI bleeding/inflammation;
- OB: Use cautiously during pregnancy (consider effects on vitamins/nutrient and potential iron overload);
- Lactation: Consider possible iron transport into milk;
- Pedi: Safety and effectiveness not established.
Adverse Reactions/Side Effects
GI: diarrhea, discolored feces, nausea, constipation, vomiting
Hemat: iron overload
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
PO (Adults) 2 tablets (2 g ferric citrate) 3 times daily. Adjust by 1–2 tablets/day at weekly (or longer) intervals to attain and maintain target phosphorous levels (max = 12 tablets/day).
Iron Deficiency Anemia
PO (Adults) 1 tablet (1 g ferric citrate) 3 times daily. Adjust dose as needed to attain and maintain target hemoglobin levels (max = 12 tablets/day).
Availability (generic available)
Tablets: 1 g (contains 210 mg ferric iron)
- Monitor clinical responses or blood levels of concurrent medications; may decrease bioavailability of medications administered concurrently.
Lab Test Considerations: Monitor serum phosphorous prior to starting and periodically during therapy to keep serum phosphorous at target levels.
- Assess iron parameters (serum ferritin and transferritin saturation TSAT) prior to starting and periodically during therapy. May cause ↑ serum ferritin and TSAT requiring reduced dose or discontinuation of IV iron therapy.
- Deficient knowledge, related to medication regimen (Patient/Family/Teaching)
- PO Administer 3 times daily with meals. Swallow tablets whole; do not crush or chew; may cause discoloration of mouth and teeth. Titrate doses no less than weekly.
- Instruct patient to take ferric citrate as directed and to continue with prescribed diet.
- Advise patient that ferric citrate may cause dark stools; this is normal for medications containing iron.
- Inform patient that ferric citrate may cause diarrhea, nausea, constipation, and vomiting. Notify health care professional if GI symptoms become severe or persistent.
- Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult with health care professional before taking other medications. Medications may need to be taken separately from ferric citrate.
- Advise patient to store ferric citrate out of the reach of children; if accidentally ingested by a child seek immediate medical attention.
- Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.
Normal serum phosphorous levels.
Anesthesia Central is an all-in-one web and mobile solution for treating patients before, during, and after surgery. This collection of drug, procedures and test information is derived from Davis’s Drug, MGH Clinical Anesthesia Procedures, Pocket Guide to Diagnostic Tests, and MEDLINE Journals. Complete Product Information.